The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
In a pivotal head-to-head trial, Novo Nordisk's next-generation obesity drug CagriSema delivered 23% body weight reduction over 84 weeks, missing the mark against Eli Lilly's tirzepatide at 25.5%. This setback highlights the intense competition in the weight-loss market. Novo shares dropped 11%, while Lilly's rose 4%.
Hims & Hers is acquiring Australian telehealth firm Eucalyptus for $1.15 billion to fuel global growth amid U.S. regulatory scrutiny over compounded GLP-1s. Experts call it a smart diversification move that complements weight loss and wellness services. This expansion could reshape access to personalized care worldwide.
Hims & Hers briefly launched a $49 compounded version of Novo Nordisk's Wegovy, prompting swift FDA backlash and a DOJ referral. Experts say the US could impose fines or injunctions for violating drug laws, though Hims' quick retreat might limit action. This highlights tensions between compounded GLP-1s and approved weight-loss drugs amid surging demand.
Researchers have identified potential concerns with oral semaglutide after an animal study showed biological changes from non-active formulation components. Unlike injections such as Ozempic or Wegovy, pills use excipients and absorption enhancers that may introduce unintended effects. This early warning calls for further human evaluation.
Katy Perry's noticeable weight loss transformation starting in 2023 has fans speculating about Ozempic use, even as she credits diet and hydration. Online chatter about 'Ozempic face' intensified after her 2024 performances and social media posts. Despite denials from Perry and sources, rumors persist into 2025.
Healthify, built on coaching, stands at the cusp of transformation as GLP-1 drugs like semaglutide prepare for patent expiry in India by 2026. Deloitte India's Srikanth Mahadevan forecasts 120,000-150,000 incremental patients in diabetes and weight management. This shift could make premium therapies accessible, fueling coaching platforms' growth.
Wegovy's explosion on TikTok and US headlines promises dramatic weight loss, but the reality involves high costs, pharmacy shortages, and the need for medical supervision. As a higher-dose semaglutide GLP-1 agonist approved for obesity, it offers double-digit weight loss in trials—but stopping it often leads to regain. US experts urge viewing it as chronic disease management, not a casual 'slimming trend.'
A groundbreaking study from Adelaide University is raising questions about SNAC, the ingredient making oral weight-loss drugs like semaglutide tablets viable. In a 21-day animal model, repeated SNAC exposure linked to lower beneficial gut bacteria, reduced protective compounds, and elevated inflammation markers. As tablet versions gain popularity, experts call for more research on this component's full impact.
The weight-loss drug Mounjaro's active ingredient, tirzepatide, is showing promise beyond metabolic health by slashing alcohol intake in animal models. A new study from the University of Gothenburg found it reduced voluntary consumption by over 50%, curbed binge drinking, and prevented relapse. This could signal a new avenue for treating alcohol use disorder through GLP-1/GIP receptor agonism.
